Lisa S. Ang

Lisa S. Ang

Auto-generated profile, based on publicly available information

Lisa S. Ang

Division of Human Biology Fred Hutchinson Cancer Center 1100 Fairview Ave. N 98109 Seattle WA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
NSNavonil De Sarkar
Navonil De Sarkar
RPRobert D. Patton
Robert D. Patton
ADAnna-Lisa Doebley
Anna-Lisa Doebley
BHBrian Hanratty
Brian Hanratty
MAMohamed Adil
Mohamed Adil
GHGavin Ha
Gavin Ha
Advanced prostate cancers comprise distinct phenotypes, but tumor classification remains clinically challenging. Here, we harnessed circulating tumor DNA (ctDNA) to study tumor phenotypes by ascertaining nucleosome positioning patterns associated with transcription regulation. We sequenced plasma ctDNA whole genomes from patient-derived xenografts representing a spectrum of androgen receptor active (ARPC) and neuroendocrine (NEPC) prostate cancers. Nucleosome patterns associated with transcriptional activity were reflected in ctDNA at regions of genes, promoters, histone modifications, transcription factor binding, and accessible chromatin. We identified the activity of key phenotype-defining transcriptional regulators from ctDNA, including AR, ASCL1, HOXB13, HNF4G, and GATA2. To distinguish NEPC and ARPC in patient plasma samples, we developed prediction models that achieved accuracies of 97% for dominant phenotypes and 87% for mixed clinical phenotypes. Although phenotype classification is typically assessed by IHC or transcriptome profiling from tumor biopsies, we demonstrate that ctDNA provides comparable results with diagnostic advantages for precision oncology. Significance: This study provides insights into the dynamics of nucleosome positioning and gene regulation associated with cancer phenotypes that can be ascertained from ctDNA. New methods for classification in phenotype mixtures extend the utility of ctDNA beyond assessments of somatic DNA alterations with important implications for molecular classification and precision oncology. This article is highlighted in the In This Issue feature, p. 517

17 January 2023 in Nature Reviews Urology
Verified
Journal Article
Closed access
PDF file
MLMitchell Lawrence
Mitchell Lawrence
RTRenea A. Taylor
Renea A. Taylor
GCGeorgia B. Cuffe
Georgia B. Cuffe
LALisa S. Ang
Lisa S. Ang
ACAshlee K. Clark
Ashlee K. Clark
Gail RisbridgerGail Risbridger
Gail Risbridger

2 May 2022 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
RPRadhika A. Patel
Radhika A. Patel
ICIlsa Coleman
Ilsa Coleman
MRMartine P. Roudier
Martine P. Roudier
EKEric Q Konnick
Eric Q Konnick
BHBrian Hanratty
Brian Hanratty
MHMichael C. Haffner
Michael C. Haffner
Anaplastic lymphoma kinase (ALK) is a tyrosine kinase with genomic and expression changes in many solid tumors. ALK inhibition is the first-line therapy for lung cancers with ALK alterations, and an effective therapy in other tumor types, but has not been well-studied in prostate cancer. Here, we aim to delineate the role of ALK genomic and expression changes in primary and metastatic prostate cancer. We determined ALK expression by IHC and RNA sequencing, and genomic alterations by NGS. We assessed functional consequences of ALK overexpression and pharmacologic ALK inhibition by cell proliferation and cell viability assays. Among 372 primary prostate cancer cases, we identified one case with uniformly high ALK protein expression. Genomic analysis revealed a novel SLC45A3-ALK fusion which promoted oncogenesis in in vitro assays. We observed ALK protein expression in 5 of 52 (9%) of metastatic prostate cancer cases, of which 4 of 5 had neuroendocrine features. ALK-expressing neuroendocrine prostate cancer had a distinct transcriptional program, and earlier disease progression. An ALK-expressing neuroendocrine prostate cancer model was sensitive to pharmacologic ALK inhibition. In summary, we found that ALK overexpression is rare in primary prostate cancer, but more frequent in metastatic prostate cancers with neuroendocrine differentiation. Furthermore, ALK fusions similar to lung cancer are an occasional driver in prostate cancer. Our data suggest that ALK-directed therapies could be an option in selected patients with advanced prostate cancer.Significance: Anaplastic lymphoma kinase (ALK) is a validated drug target in cancer. Here we delineate the spectrum of ALK alterations in prostate cancer. We show that ALK overexpression is present in advanced prostate cancers, in particular in cases with features of neuroendocrine carcinoma. Furthermore, ALK expression is associated with responses to pharmacologic ALK inhibition. Our study demonstrates that ALK-directed therapies should be considered in selected prostate cancer cases.

29 August 2025 in Science Advances
Verified
Journal Article
Open access
NGNicole Gregorio
Nicole Gregorio
FZFan Zhang
Fan Zhang
YSYusuke Suita
Yusuke Suita
LALisa S. Ang
Lisa S. Ang
OPOlivia Prado
Olivia Prado
CDCole A. DeForest
Cole A. DeForest
Hydrogel biomaterials offer great promise for three-dimensional cell culture and therapeutic delivery. Despite many successes, challenges persist in that gels formed from natural proteins are only marginally tunable whereas those derived from synthetic polymers lack intrinsic bioinstructivity. Toward the creation of biomaterials with both excellent biocompatibility and customizability, recombinant protein–based hydrogels have emerged as molecularly defined and user-programmable platforms that mimic the proteinaceous nature of the extracellular matrix. Here, we introduce PhoCoil, a dynamically tunable recombinant hydrogel formed from a single protein component with unique multistimuli responsiveness. Physical cross-linking through coiled-coil interactions promotes rapid shear-thinning and self-healing behavior, rendering the gel injectable, whereas an included photodegradable motif affords on-demand network dissolution via visible light. PhoCoil gel photodegradation can be spatiotemporally and lithographically controlled in a dose-dependent manner, through complex tissue, and without harm to encapsulated cells. We anticipate that PhoCoil will further enable applications in tissue engineering and regenerative medicine.

15 April 2026 in Blood Neoplasia
Verified
Journal Article
Open access
SMShelli M. Morris
Shelli M. Morris
KPKristina Pilat
Kristina Pilat
EGEmily J. Girard
Emily J. Girard
ANAlyssa Noll
Alyssa Noll
LALisa S. Ang
Lisa S. Ang
JOJames M. Olson
James M. Olson

4 April 2023
Verified
Other
Open access
NSNavonil De Sarkar
Navonil De Sarkar
RPRobert D. Patton
Robert D. Patton
ADAnna-Lisa Doebley
Anna-Lisa Doebley
BHBrian Hanratty
Brian Hanratty
MAMohamed Adil
Mohamed Adil
GHGavin Ha
Gavin Ha
Supplementary Figures S1-S18 and Supplementary Table legends.